RS51138B - S-mirtazapin za lečenje nastupa vreline (valunga) - Google Patents

S-mirtazapin za lečenje nastupa vreline (valunga)

Info

Publication number
RS51138B
RS51138B RSP-2009/0504A RSP20090504A RS51138B RS 51138 B RS51138 B RS 51138B RS P20090504 A RSP20090504 A RS P20090504A RS 51138 B RS51138 B RS 51138B
Authority
RS
Serbia
Prior art keywords
treatment
mirtazapine
rats
vasomotor symptoms
week
Prior art date
Application number
RSP-2009/0504A
Other languages
English (en)
Serbian (sr)
Inventor
Bernardus PEETERS B.W.M.M.
Anton Egbert Peter Adang
Original Assignee
N.V. Organon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34929859&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS51138(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by N.V. Organon filed Critical N.V. Organon
Publication of RS51138B publication Critical patent/RS51138B/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
RSP-2009/0504A 2004-11-15 2005-11-14 S-mirtazapin za lečenje nastupa vreline (valunga) RS51138B (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04105778 2004-11-15
PCT/EP2005/055947 WO2006051111A1 (en) 2004-11-15 2005-11-14 S-mirtazapine for the treatment of hot flush

Publications (1)

Publication Number Publication Date
RS51138B true RS51138B (sr) 2010-10-31

Family

ID=34929859

Family Applications (1)

Application Number Title Priority Date Filing Date
RSP-2009/0504A RS51138B (sr) 2004-11-15 2005-11-14 S-mirtazapin za lečenje nastupa vreline (valunga)

Country Status (30)

Country Link
US (4) US20070265245A1 (enExample)
EP (1) EP1814555B1 (enExample)
JP (1) JP2008519810A (enExample)
KR (1) KR20070085470A (enExample)
CN (2) CN101056641A (enExample)
AR (1) AR053780A1 (enExample)
AT (1) ATE439843T1 (enExample)
AU (1) AU2005303778B2 (enExample)
BR (1) BRPI0517818A2 (enExample)
CA (1) CA2587283C (enExample)
CY (1) CY1110538T1 (enExample)
DE (1) DE602005016141D1 (enExample)
DK (1) DK1814555T3 (enExample)
ES (1) ES2329815T3 (enExample)
HR (1) HRP20090513T1 (enExample)
IL (1) IL182767A (enExample)
MX (1) MX2007005827A (enExample)
MY (1) MY144089A (enExample)
NO (1) NO20072285L (enExample)
NZ (1) NZ554858A (enExample)
PE (1) PE20061051A1 (enExample)
PL (1) PL1814555T3 (enExample)
PT (1) PT1814555E (enExample)
RS (1) RS51138B (enExample)
RU (1) RU2396957C2 (enExample)
SI (1) SI1814555T1 (enExample)
TW (1) TW200631584A (enExample)
UA (1) UA88655C2 (enExample)
WO (1) WO2006051111A1 (enExample)
ZA (1) ZA200703884B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007002174A2 (en) * 2005-06-27 2007-01-04 N.V. Organon. A method of treatment of hormone depletion induced vasomotor symptoms
US20070129611A1 (en) * 2005-12-06 2007-06-07 University Of North Texas Health Science Center At Fort Worth System, Method and Apparatus for Assessing Menopausal or Post-Hysterectomy Symptoms
EP1993556A1 (en) * 2006-03-06 2008-11-26 N.V. Organon An improved method of weaning from hormonal treatment of hormone depletion induced vasomotor symptoms
AU2007324467A1 (en) * 2006-11-22 2008-05-29 N.V. Organon Vaginal delivery system for mirtazapine
US7645750B2 (en) * 2006-12-13 2010-01-12 Yung Shin Pharmaceutical Ind. Co., Ltd. Method of treating symptoms of hormonal variations
JP2009018992A (ja) 2007-07-10 2009-01-29 Sumitomo Chemical Co Ltd 光学活性ミルタザピンの製造方法
US8420624B2 (en) 2007-12-04 2013-04-16 Yung Shin Pharm. Ind. Co., Ltd. Methods for treating or preventing symptoms of hormonal variations
JP6876003B2 (ja) 2015-02-27 2021-05-26 デクラ リミテッド イヌ及びネコにおける、食欲の刺激、体重減少の管理、及び拒食症の処置
KR102608479B1 (ko) * 2017-05-25 2023-12-01 글리테크 엘엘씨. Nmdar 길항제-반응성 신경정신 질환을 위한 병용 요법
WO2021167579A1 (ru) 2020-02-19 2021-08-26 Иван УЛИНИЧ Универсальное устройство для тепловой обработки пищевых продуктов

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL189199C (nl) * 1975-04-05 1993-02-01 Akzo Nv Werkwijze ter bereiding van farmaceutische preparaten met werking op het centraal zenuwstelsel op basis van benz(aryl)azepinederivaten, de verkregen gevormde farmaceutische preparaten, alsmede werkwijze ter bereiding van de toe te passen benz(aryl)azepinederivaten.
US4515792A (en) * 1982-09-30 1985-05-07 Ciba-Geigy Corporation Tetracyclic heterocycles and antidepressant compositions thereof
JPH1187727A (ja) * 1997-09-12 1999-03-30 Mitsubishi Electric Corp 半導体装置
ES2212550T3 (es) * 1998-04-02 2004-07-16 Akzo Nobel N.V. Solucion oral liquida que comprende el antidepresor mirtazapina.
RU2195951C1 (ru) * 2001-08-20 2003-01-10 Общество с ограниченной ответственностью "Лаборатория "Ирис" Средство для лечения климактерических расстройств

Also Published As

Publication number Publication date
AR053780A1 (es) 2007-05-23
CN102772414A (zh) 2012-11-14
MX2007005827A (es) 2007-07-20
ES2329815T3 (es) 2009-12-01
CA2587283A1 (en) 2006-05-18
EP1814555B1 (en) 2009-08-19
CA2587283C (en) 2013-01-15
US20100267694A1 (en) 2010-10-21
HRP20090513T1 (hr) 2009-10-31
US20070265245A1 (en) 2007-11-15
PT1814555E (pt) 2009-09-30
NZ554858A (en) 2009-10-30
ATE439843T1 (de) 2009-09-15
PL1814555T3 (pl) 2010-01-29
IL182767A (en) 2011-07-31
KR20070085470A (ko) 2007-08-27
PE20061051A1 (es) 2006-10-26
MY144089A (en) 2011-08-15
CY1110538T1 (el) 2015-04-29
IL182767A0 (en) 2007-09-20
UA88655C2 (ru) 2009-11-10
NO20072285L (no) 2007-06-13
CN101056641A (zh) 2007-10-17
RU2396957C2 (ru) 2010-08-20
US20120302552A1 (en) 2012-11-29
HK1104235A1 (en) 2008-01-11
US20130225559A1 (en) 2013-08-29
DE602005016141D1 (de) 2009-10-01
AU2005303778A1 (en) 2006-05-18
EP1814555A1 (en) 2007-08-08
AU2005303778B2 (en) 2011-02-17
RU2007122391A (ru) 2008-12-20
JP2008519810A (ja) 2008-06-12
DK1814555T3 (da) 2009-12-07
SI1814555T1 (sl) 2009-12-31
WO2006051111A1 (en) 2006-05-18
ZA200703884B (en) 2009-07-29
TW200631584A (en) 2006-09-16
BRPI0517818A2 (pt) 2010-03-16

Similar Documents

Publication Publication Date Title
US20120302552A1 (en) S-mirtazapine for the treatment of hot flush
WO2016062283A1 (zh) 抗发炎用药物在制备抑制癌症的医药组合物中的应用
JP6137833B2 (ja) 脱髄性および他の神経系疾患を患っている患者における神経認知的および／または神経精神医学的障害を改善するための４−アミノピリジンの使用
US20250205186A1 (en) Use of chlorogenic acid in preparing medicine or pharmaceutical composition for preventing or treating pain
JP2010501581A (ja) 神経細胞の損傷を減少させる方法
TW201540299A (zh) 以螺－吲哚酮化合物之局部製劑治療與關節之骨關節炎相關的疼痛之方法
CN110279691B (zh) 一种外科术后护理镇痛药物及其用途
CN114948980A (zh) 一种预防和/或治疗焦虑性失眠的药物组合物及其应用
TWI404542B (zh) 用於治療抽動症及具有感覺運動門控不良之精神疾病的海州常山屬組合物
CN102283834B (zh) 一种含奥利司他的药物组合物及用途
CN104706639B (zh) 一种治疗雄性勃起功能障碍的药物组合物及其用途
Mukand et al. Olanzapine for the treatment of hemiballismus: A case report
CN115531365B (zh) 绿原酸组合物在制备预防或治疗疼痛的药物中的用途
HK1104235B (en) S-mirtazapine for the treatment of hot flush
JP2008044879A (ja) ラクトフェリンを含有する医薬組成物ならびに加工食品
EP2397126A1 (en) Pharmaceutical composition containing glur2-lacking ampar antagonist for preventing or treating psychiatric illnesses
Garrido-Suárez et al. Report of cases in patients with acute herpetic neuralgia using a Mangifera indica extract
CN115969850A (zh) 小檗胺在制备镇痛药物中的应用
Covyeou et al. Case report of severe injection site reaction associated with intramuscular naltrexone
Debatisse et al. Pain stimulation by using synchronised somatosensory evoked potentials (SSEPs) and contact heat evoked potentials (CHEPs): A-710
Jeon et al. Cell therapy for management of chronic pain: A-709
DE202008002797U1 (de) Medikamentengestützter Nikotinentzug
CN106860518A (zh) 治疗烧伤烫伤的药物及其制备方法
CN102526269A (zh) 一种治疗中老年遗尿症的药用食物及制备方法